Industries

We know that Basel II, III and IV are not city districts. We have advised insurance companies that had to explain substantial reserve increases to the capital market. And financial institutions that received letters from Finma. International asset managers engage us to increase visibility or sharpen their profile. So we are familiar with the industry-specific issues and players.

PS: Benjamin Mühlemann knows financial policy inside out.

PPS: Anyone who wants to get to know the Basel city districts better is in the right place with Valentin Handschin.

We know that in this world, things do not revolve around their own axis but around shelf space at the point of sale. We have advised consumer goods companies on positioning in the capital market. Or in trademark disputes. In the process, among other things, we discovered that calibres and complications are not only common to the watch industry, but also to the management of reputations.

PS: René Weber knows a great deal about balance wheels and calibres.

We know that engineers speaking of tolerance typically do not have the behavior of kids in mind. That shear force often leads to material failure. We have supported many industrial companies in acquisitions and divestments, IPOs, cyberattacks, CEO and ownership changes - or often simply with the next enquiry from NZZ, Rundschau, Bilanz, Blick and the like.

We know that SaaS is not a misspelled mountain resort. That printed circuit boards are only of limited use when climbing mountains in Saas. We have supported technology companies on the steep path to the stock exchange (more than once) and on the path to the bankruptcy judge (once). We had heard of disruptive innovation before it became a buzzword.

We know that biotech companies do not mean the alternating current when they talk about Phase I, II or III. And that these phases usually take longer than originally planned. We have advised companies that came under criticism because of the use of greenhouse gases or rare earths. And others that want to be prepared for every scenario in the approval process with the FDA and EMA.

PS: Yasemin Diethelm-Ersan is our specialist for the medtech industry.

We know that in this industry, cash cows are more commonly found in city centres than on alpine pastures. That cap rates are not price tags on hats. That Lex Koller has many lives in the Federal Parliament. We have communicatively guided a wide range of real estate projects through appeals and instances. And have given representatives of this industry a voice in the rough-and-tumble world of politics.